How GLP-1s are more than just weight-loss wonders – but not without risk
Not long ago, nobody was talking about GLP-1 receptor agonists. Most of us did not even know what…
How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…